Plain-English translation of NCT06857214 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called , which is a type of antibody designed to help control the immune system in people with systemic lupus erythematosus (lupus). The trial has two phases: first, researchers will test the medication's safety and how the body processes it, and then they will compare it to an existing lupus treatment to see if it works better. The goal is to find out if this medication can reduce lupus symptoms and disease activity with manageable side effects.
Lupus is a serious autoimmune disease where the body attacks its own tissues, causing inflammation and damage. While some treatments exist, they don't work well enough for everyone, and doctors need new options that are safer and more effective. This trial is testing whether the medication can target the immune cells that cause lupus without causing too much harm to the rest of the body.
You likely qualify if…
You likely don't qualify if…
Participants will receive injections of the medication and be monitored closely with blood tests and clinic visits to check for safety and effectiveness. Some participants may receive additional treatment cycles if they benefit from the first one, while others in a later phase of the study will receive an existing lupus medication for comparison. The study will track how well the medication works, how the body processes it, and what side effects occur, continuing until the treatment stops helping, side effects become too severe, or the study ends.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Enrollment target
~84 participants
Started
June 2025
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sa Xiao, PHD
Sichuan Baili Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.